AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29678971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified intervention
Number of subjects: 19
Study 29678971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Behaviour Change Techniques
Number of subjects: 19
Study 29679103 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A*24 positivity
Number of subjects: 40
Study 29679103 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC30A8 CT or TT genotypes
Number of subjects: 40
Study 29679103 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI more than or equal to the group median (23.9 kg/m²)
Number of subjects: 40
Study 29680101 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI-DaySyms (13-item draft daily diary)
Number of subjects: 34
Study 29680101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive interviews (stage 2)
Number of subjects: 34
Study 29680471 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring
Number of subjects: 127
Study 29680471 — intervention group
Group type: EXPERIMENTAL
Intervention: aEEG monitoring
Number of subjects: 127
Study 29680676 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid users
Number of subjects: 437
Study 29680676 — intervention group
Group type: COMPARATOR
Intervention: Alcohol detoxification seekers
Number of subjects: 437
Study 29680811 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based education (high-fidelity simulation)
Number of subjects: 0
Study 29680880 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-122 (preservative-free fixed combination)
Number of subjects: 51
Study 29680880 — intervention group
Group type: COMPARATOR
Intervention: KOF (0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination)
Number of subjects: 51
Study 29680880 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-122
Number of subjects: 51
Study 29680880 — intervention group
Group type: COMPARATOR
Intervention: KOF
Number of subjects: 51
Study 29680880 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-122 and KOF
Number of subjects: 51
Study 29680881 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg daily
Number of subjects: 1430
Study 29680881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1430
Study 29681462 — intervention group
Group type: EXPERIMENTAL
Intervention: Onclarity HPV assay
Number of subjects: 33858
Study 29681490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (120 mg twice daily on days one to seven; 240 mg twice a day thereafter)
Number of subjects: 22
Study 29681490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Number of subjects: 22
Study 29681762 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttreatment (POST) group with increased p53 nuclear/cytoplasmic (N/C) ratio
Number of subjects: 60
Study 29681762 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched pairs (MP) group
Number of subjects: 60
Study 29681762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment (PRE) group
Number of subjects: 60
Study 29681866 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-brain stimulation (DBS) to the nucleus accumbens (NAcc)
Number of subjects: 6
Study 29681866 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS to the NAcc
Number of subjects: 6
Study 29681973 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Number of subjects: 0
Study 29681973 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Hypopressive Gymnastics
Number of subjects: 0
Study 29681973 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Massage Therapy and Abdominal Hypopressive Gymnastics
Number of subjects: 0
Study 29681973 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29681977 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Week Intervention
Number of subjects: 0
Study 29682131 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint used for about 20 hours over a 4-month period
Number of subjects: 112
Study 29682131 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive therapy using a biostimulation laser over 12 sessions performed every second day
Number of subjects: 112
Study 29682277 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat-PAD (6 nmol) administered via four monthly injections
Number of subjects: 19
Study 29682294 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraGraft treatment
Number of subjects: 0
Study 29682294 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 0
Study 29682332 — intervention group
Group type: COMPARATOR
Intervention: EGFR inhibitors
Number of subjects: 0
Study 29682332 — intervention group
Group type: COMPARATOR
Intervention: ALK inhibitors
Number of subjects: 0
Study 29682332 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD1 inhibitors
Number of subjects: 0
Study 29682332 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 29682773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (higher daily doses)
Number of subjects: 2034
Study 29682773 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal crisis (AC)
Number of subjects: 2034
Study 29682773 — intervention group
Group type: COMPARATOR
Intervention: Demographics and clinical characteristics
Number of subjects: 2034
Study 29682773 — intervention group
Group type: COMPARATOR
Intervention: Causes of death
Number of subjects: 2034
Study 29683544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosed folate supplements (5 mg folic acid per day)
Number of subjects: 318
Study 29683544 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements (200 mg ferrous sulphate per day)
Number of subjects: 318
Study 29683562 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral osimertinib 80 mg
Number of subjects: 10
Study 29683562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) osimertinib 100 μg microtracer dose
Number of subjects: 10
Study 29683703 — intervention group
Group type: EXPERIMENTAL
Intervention: STAMP (anxiety sensitivity reduction-smoking cessation intervention)
Number of subjects: 529
Study 29683703 — intervention group
Group type: COMPARATOR
Intervention: SCP (standard smoking cessation intervention)
Number of subjects: 529
Study 29683790 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyamidotriazole orotate (CTO)
Number of subjects: 0
Study 29683790 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study 29683984 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses (PAL)
Number of subjects: 64
Study 29683984 — intervention group
Group type: COMPARATOR
Intervention: Single-Vision Lenses (SVL)
Number of subjects: 64
Study 29684022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of ceftriaxone and azithromycin
Number of subjects: 105
Study 29684022 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with ceftriaxone
Number of subjects: 105
Study 29684022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of azithromycin and cefexime
Number of subjects: 105
Study 29684022 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with azithromycin
Number of subjects: 105
Study 29684022 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 105
Study 29684662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensives
Number of subjects: 41
Study 29684662 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicomechanical factors
Number of subjects: 41
Study 29684662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical endothelial injury
Number of subjects: 41
Study 29684739 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Land Data Assimilation System (GLDAS)
Number of subjects: 8
Study 29684739 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate Hazards Group InfraRed Precipitation with Stations (CHIRPS)
Number of subjects: 8
Study 29684739 — intervention group
Group type: COMPARATOR
Intervention: Weather-station derived estimates
Number of subjects: 8
Study 29684739 — intervention group
Group type: COMPARATOR
Intervention: Earth Observation (EO) derived estimates
Number of subjects: 8
Study 29684764 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety and higher perceptions that peers drink heavily
Number of subjects: 1254
Study 29684764 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depression and perceptions of peers' drinking
Number of subjects: 1254
Study 29684764 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes that peers approve of heavy drinking
Number of subjects: 1254
Study 29685114 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR-901
Number of subjects: 0
Study 29685114 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29685124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analyses System of Psychotherapy (CBASP)
Number of subjects: 255
Study 29685124 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 255
Study 29685478 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial increase in lipopolysaccharides (LPS) levels in the Incident-DIAB group at baseline
Number of subjects: 462
Study 29685478 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS postprandial fold change combined with FINDRISC score
Number of subjects: 462
Study 29685478 — intervention group
Group type: COMPARATOR
Intervention: FINDRISC score alone
Number of subjects: 462
Study 29685594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxem™ Hib (intramuscular injection)
Number of subjects: 31
Study 29685860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (goal <120 mm Hg) in ACCORD trial
Number of subjects: 11026
Study 29685860 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure control (goal <140 mm Hg) in ACCORD trial
Number of subjects: 11026
Study 29685860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure control (goal <120 mm Hg) in SPRINT trial
Number of subjects: 11026
Study 29685860 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure control (goal <140 mm Hg) in SPRINT trial
Number of subjects: 11026
Study 29685863 — intervention group
Group type: EXPERIMENTAL
Intervention: iPhone gaming intervention
Number of subjects: 20
Study 29685882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 29685935 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Sensitivity Cardiac Troponin T with sex-specific cutoff values
Number of subjects: 0
Study 29685935 — intervention group
Group type: COMPARATOR
Intervention: Standard High-Sensitivity Cardiac Troponin T cutoff values
Number of subjects: 0
Study 29686173 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment for diabetes
Number of subjects: 374
Study 29686883 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating needle group
Number of subjects: 6
Study 29686883 — intervention group
Group type: COMPARATOR
Intervention: Skin-touch placebo control group
Number of subjects: 6
Study 29686883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6
Study 29687077 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection intrathecal analgesia (IA)
Number of subjects: 601
Study 29687277 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral perfusion-targeted resuscitation
Number of subjects: 422
Study 29687277 — intervention group
Group type: COMPARATOR
Intervention: Lactate-targeted resuscitation
Number of subjects: 422
Study 29687341 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference
Number of subjects: 120
Study 29688815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular infusion of cerliponase alfa (30 mg, 100 mg, or 300 mg, with all patients receiving 300 mg for at least 96 weeks)
Number of subjects: 24
Study 29688815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular infusion of cerliponase alfa
Number of subjects: 24
Study 29688815 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (42 patients)
Number of subjects: 24
Study 29688843 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 600
Study 29688843 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization and costs
Number of subjects: 600
Study 29688843 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and caregiver preferences
Number of subjects: 600
Study 29688843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement adjustment measurement
Number of subjects: 600
Study 29689135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0.9mg/kg)
Number of subjects: 80
Study 29689174 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfortable Cafeteria program led by occupational therapists for 6 weeks
Number of subjects: 0
Study 29689485 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dronabinol (180-240 mg/day; 60-80 mg tid)
Number of subjects: 13
Study 29689485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dronabinol (120 mg/day; 40 mg tid)
Number of subjects: 13
Study 29689485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29690880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function test (PFT) abnormalities at baseline
Number of subjects: 52
Study 29690880 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower forced expiratory volume in one second after bronchodilator
Number of subjects: 52
Study 29690880 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCO (carbon monoxide diffusing capacity)
Number of subjects: 52
Study 29690880 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO
Number of subjects: 52
Study 29690880 — intervention group
Group type: EXPERIMENTAL
Intervention: PFT results after CCRT
Number of subjects: 52
Study 29690927 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coil helmet (transcranial LED stimulation, 627 nm, 70 mW/cm²)
Number of subjects: 32
Study 29690927 — intervention group
Group type: COMPARATOR
Intervention: Inactive coil (sham)
Number of subjects: 32
Study 29690930 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of ERTTAC
Number of subjects: 1378
Study 29690930 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting the criterion 'passenger of car or truck'
Number of subjects: 1378
Study 29691182 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive protective drapes
Number of subjects: 122
Study 29691182 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive protective drapes (implied control)
Number of subjects: 122
Study 29691250 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 365
Study 29691250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 29691270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations.
Number of subjects: 0
Study 29691270 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI and hs-cTnT concentrations with optimized cut-off values (sum: 9 ng/L, product: 18 ng/L).
Number of subjects: 0
Study 29691270 — intervention group
Group type: COMPARATOR
Intervention: European Society of Cardiology 2015 guideline recommended algorithms and cut-offs.
Number of subjects: 0
Study 29691300 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab/GS-5745 alone
Number of subjects: 0
Study 29691300 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab/GS-5745 combined with mFOLFOX6
Number of subjects: 0
Study 29691300 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 alone
Number of subjects: 0
Study 29692311 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis
Number of subjects: 70
Study 29692935 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium hydroxyapatite (Sr-HA)
Number of subjects: 0
Study 29692935 — intervention group
Group type: COMPARATOR
Intervention: Polymethacrylate (PMMA)
Number of subjects: 0
Study 29692980 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI-sponsored uterine cervix cancer radiation-chemotherapy intervention clinical trial (NCT02466971)
Number of subjects: 0
Study 29693360 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPA-REG OUTCOME (empagliflozin)
Number of subjects: 23941512
Study 29693360 — intervention group
Group type: EXPERIMENTAL
Intervention: VERTIS-CV (ertugliflozin)
Number of subjects: 23941512
Study 29693360 — intervention group
Group type: EXPERIMENTAL
Intervention: CANVAS program (canagliflozin)
Number of subjects: 23941512
Study 29693360 — intervention group
Group type: EXPERIMENTAL
Intervention: DECLARE-TIMI 58 (dapagliflozin)
Number of subjects: 23941512
Study 29693361 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 RA CVOTs (including ELIXA, EXSCEL, FREEDOM-CVO, HARMONY Outcomes, LEADER, REWIND, SUSTAIN-6)
Number of subjects: 0
Study 29693361 — intervention group
Group type: EXPERIMENTAL
Intervention: EXSCEL (Exenatide Study of Cardiovascular Event Lowering)
Number of subjects: 0
Study 29693361 — intervention group
Group type: EXPERIMENTAL
Intervention: ELIXA (lixisenatide)
Number of subjects: 0
Study 29693476 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1500 mg/d for 7 days)
Number of subjects: 36
Study 29693476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (1500 mg/d for 7 days)
Number of subjects: 36
Study 29693476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1500 mg/d for 7 days)
Number of subjects: 36
Study 29693715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (5 mg for 5 days followed by 10 mg for 5 days)
Number of subjects: 56
Study 29694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 128
Study 29694241 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 128
Study 29694241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 29694241 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + Placebo
Number of subjects: 128
Study 29694241 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + ATX
Number of subjects: 128
Study 29694241 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 128
Study 29694702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 101
Study 29694948 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) measurement
Number of subjects: 1301
Study 29695165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 75 mg BID for ≥7 days
Number of subjects: 60
Study 29695375 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist cuff blood pressure device (iteratively calibrated)
Number of subjects: 20
Study 29695375 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist cuff blood pressure device (calibrated to direct aortic pressures)
Number of subjects: 20
Study 29695384 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (thrombectomy, balloon angioplasty, stenting, local fibrinolysis, piercing)
Number of subjects: 2399
Study 29695384 — intervention group
Group type: COMPARATOR
Intervention: No endovascular therapy
Number of subjects: 2399
Study 29695384 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 2399
Study 29695516 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB040093 100 mg twice daily (monotherapy)
Number of subjects: 114
Study 29695516 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination)
Number of subjects: 114
Study 29695812 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of combined endurance- and strength-exercise intervention
Number of subjects: 26
Study 29695812 — intervention group
Group type: EXPERIMENTAL
Intervention: One bicycle session
Number of subjects: 26
Study 29695812 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 26
Study 29696165 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Care Aide-led resistance exercise intervention for 6 months
Number of subjects: 126
Study 29696165 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 126
Study 29696170 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality 3 years after the ES index event
Number of subjects: 500
Study 29696170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for all causes 3 years after the ES index event
Number of subjects: 500
Study 29696170 — intervention group
Group type: EXPERIMENTAL
Intervention: ES recurrences
Number of subjects: 500
Study 29696170 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclustered VTs/VFs recurrences
Number of subjects: 500
Study 29696170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalizations for HF worsening
Number of subjects: 500
Study 29696198 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game (PAX GBG) intervention
Number of subjects: 42
Study 29696198 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 42
Study 29696202 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiviral drug AV2
Number of subjects: 0
Study 29696202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29696203 — intervention group
Group type: EXPERIMENTAL
Intervention: CREATE Wellness intervention (3 session, group-based intervention)
Number of subjects: 0
Study 29696211 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical lifestyle intervention trials
Number of subjects: 0
Study 29696211 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29696228 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity in the LIFE study
Number of subjects: 385
Study 29696228 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cranberry capsules in the CRANNY trial
Number of subjects: 385
Study 29696228 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 385